Want to see GPCR full AI Analyst Report?
GPCR Stock Chart & Stats
$50.75
-$0.32(-1.18%)
At close: 4:00 PM EST
$50.75
-$0.32(-1.18%)
Day’s Range― - ―
52-Week Range$15.80 - $94.90
Previous CloseN/A
Volume219.80K
Average Volume (3M)823.02K
Market Cap
$3.92B
Enterprise Value$2.28B
Total Cash (Recent Filing)$1.46B
Total Debt (Recent Filing)$5.79M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Aug 06, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.64
Shares Outstanding71,074,520
10 Day Avg. Volume794,664
30 Day Avg. Volume823,023
Financial Highlights & Ratios
PEG Ratio-11.30
Price to Book (P/B)2.72
Price to Sales (P/S)0.00
P/FCF Ratio-18.23
Enterprise Value/Market Cap0.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.87K
Enterprise Value/Ebitda-13.59
Forecast
1Y Price Target
$110.17Price Target Upside117.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.43
Revenue Forecast (FY)$35.71M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet With Minimal LeverageA large equity base (~$1.45B) and negligible debt materially reduce refinancing risk and give management flexibility to fund multi-year, late-stage clinical programs. This financial strength supports sustained R&D spending and strategic optionality over the next 2–6 months and beyond.
Lead Obesity Program Advancing To Phase 3Robust Phase 2 efficacy and favorable FDA end-of-Phase-2 feedback materially de-risk the development path for aleniglipron. A planned Phase 3 start clarifies timing and regulatory expectations, increasing the structural probability the company can advance toward a commercial asset if trials confirm results.
Experienced Operational Leadership HireAdding a seasoned COO/General Counsel with commercialization and global development experience strengthens execution capability for late-stage trials and eventual launch. This enhances operational readiness, regulatory navigation and potential partnering or commercial strategy over coming quarters.
Bears Say
Pre-revenue Company With Widening LossesWithout product revenues, the company relies entirely on financing to cover escalating operating losses. Widening negative EBIT highlights that profitability is distant absent successful clinical outcomes or partnerships, increasing execution and funding risk over the medium term.
Sustained Heavy Cash Burn And Negative Free Cash FlowPersistent negative operating and free cash flow indicate ongoing high funding needs to progress trials. Even with current liquidity, accelerating cash outflows pressure runway and make the company dependent on timely financing or milestone receipts, elevating medium-term dilution and execution risk.
Expanded ATM Capacity Increases Dilution RiskRemoving the issuance cap expands ability to raise equity quickly but increases structural dilution risk if management taps the ATM to fund trials. Reliance on equity markets for cash can dilute existing holders and affect long-term capital structure if clinical progress does not reduce financing needs.
Structure Therapeutics, Inc. Sponsored ADR News
GPCR FAQ
What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?
Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $15.80 and its highest was $94.90 in the past 12 months.
What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?
Structure Therapeutics, Inc. Sponsored ADR’s market cap is $3.92B.
When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?
Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.
How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?
Structure Therapeutics, Inc. Sponsored ADR released its earnings results on May 07, 2026. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.351 by $0.001.
Is Structure Therapeutics, Inc. Sponsored ADR overvalued?
According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued.
Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?
Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.
What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?
Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -0.38.
How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?
Structure Therapeutics, Inc. Sponsored ADR has 71,074,520 shares outstanding.
What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?
Structure Therapeutics, Inc. Sponsored ADR reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.351. Following the earnings report the stock price went down -0.128%.
Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?
Currently, no hedge funds are holding shares in GPCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$110.17 (117.08% Upside)
$110.17 (117.08% Upside)
Blogger Sentiment
Bullish
GPCR Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 475.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
188.69%
12-Months-Change
Fundamentals
Return on Equity
-15.14%
Trailing 12-Months
Asset Growth
74.04%
Trailing 12-Months
Company Description
Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
GPCR Stock 12 Month Forecast
Average Price Target
$110.17
▲(117.08% Upside)
Technical Analysis
Ownership Overview
10.08% Insiders
26.29% Mutual Funds
0.05% Other Institutional Investors
61.40% Public Companies and Individual Investors